Active Trials

These COVID-19 clinical trials are active and approved by Health Canada. Many more are pending approval and will be added in the days and weeks ahead.

Help us complete the circle. Add your trial to our list of active COVID-19 Canadian clinical trials and gain access to a wider participant registry.

Trial name A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
Type of trial Phase III
Trial ID NCT04348656
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon
Trial description

CONCOR-1 Trial Description: A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness. This is a prospective randomized control trial that is comparing convalescent plasma to standard of care in adult patients admitted to Canadian hospitals with respiratory complications from COVID-19. Intervention will be 500 mL of convalescent plasma from donors with SAR-CoV-2 neutralizing antibodies in addition to standard of care. We are not yet enrolling patients. There will be between 40-60 sites participating across Canada.

Study team
Donald Arnold
Donald Arnold
MD
Hamilton Health Sciences Centre
Trial name A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA)
Type of trial Phase III
Trial ID NCT 04320615
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec, Ontario
Trial description

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.

Study team
Hoffmann-La Roche Limited
Hoffmann-La Roche Limited
Hoffmann-La Roche Limited
Trial name Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)
Type of trial Phase IV
Trial ID NCT04374474
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
Ontario
Trial description

The study will be a randomized controlled trial, involving patients with hyposmia/anosmia of onset immediately after an upper respiratory viral illness, assigned to three distinct study arms. Nasal irrigations will be prescribed to all three groups (BID). In addition, one arm will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care) and act as a control group. The second group will receive an essential oil retraining kit, whereas the third group will receive the same olfactory training kit and a prescription to use budesonide with the nasal irrigations. Olfactory scores will be tested at the enrollment, 3 months and at 6 months.

Study team
Dr. Leigh Sowerby
Dr. Leigh Sowerby
MD, FRCSC
Western University
Trial name Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
Type of trial Phase III
Trial ID NCT 04324463
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario
Trial description

The ACT COVID-19 program consists of two parallel trials evaluating azithromycin and chloroquine therapy (ACT) versus usual care in outpatients and inpatients who have tested positive for COVID-19

Study team
Richard Whitlock
Richard Whitlock
MD, PhD
Population Health Research Institute
Emilie Belley-Cote
Emilie Belley-Cote
MD, PhD
Population Health Research Institute
Trial name COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir (CORIPREV-LR)
Type of trial Phase III
Trial ID NCT 04321174
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, British Columbia
Trial description

La prophylaxie post-exposition (PPE) est sujet de recherche identifié de priorité urgente par l'organization mondiale de la santé. L'association lopinavir/ritonavir (LPV/r) est candidate prometteuse pour le traitement de la COVID-19 ainsi que la PPE, tout en ayant un bon profil de sécurité et disponibilité mondiale. Cet essai randomisé controllé (ERC) par grappes de lPV/r par voix orale contre la COVID-19, répondra au besoin immédiat d'interventions de prévention, va générer des données clés au sujet de la transmission de la COVID-19, et servira de plateforme de recherche pour les vaccins et agents préventifs futur.

Study team
Darrell Tan
Darrell Tan
MD, FRCPC.PhD
St Michael’s Hospital
Trial name CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION
Type of trial Phase III
Trial ID NCT04333732
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
Ontario
Trial description

Healthcare workers are at the frontline of the fight against COVID-19, and as such they are at high risk for infection and possibly for serious infection, linked to the extent of their exposure. The CROWN CORONATION trial prioritizes the protection of healthcare workers as a strategy to prevent collapse of healthcare services.

Study team
spence
Dr. Jessica Spence
MD
Population Health Resarch Institute
David Mazer
Dr. David Mazer
MD
University of Toronto
Trial name Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial
Type of trial Not Applicable
Trial ID NCT04359264
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
Ontario
Trial description

This is a clinical trial of a cash transfer on symptoms consistent with COVID-19 and adherence to physical distancing guidance.

Study team
Mike Bedard
Dr. Mike Bedard
MD
Municipality of Assiginack Family Health Team
Nav Persaud
Dr. Nav Persaud
MD
St Michael's Hospital Academic Family Health Team
Trial name Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Type of trial Phase II
Trial ID NCT 04315298
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
United States, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon
Trial description

The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of severity strata. (This initiative also has pan-Canadian sites.)

Study team
Trial name Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD)
Type of trial Phase II
Trial ID NCT04354259
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario
Trial description

The study uses an adaptive design with initial enrolment in the Ambulatory cohort (Cohort A) followed by a safety assessment before initiation of enrolment in the Hospitalized cohort (Cohort B). Ambulatory patients (Cohort A) with confirmed COVID-19 deemed well enough for home isolation will be randomized to receive a single subcutaneous injection of Peginterferon lambda 180µg prior to discharge or no therapy. Patients will be followed remotely with a home visit for a repeat swab at Day 4 and 8 with the primary endpoint being the proportion positive for SARS-CoV-2 on Day 8. Safety data will be reviewed by the Data Safety and Monitoring Committee after 50% of the Ambulatory cohort (n=60) has been enrolled. If the committee approves study continuation, enrolment will continue in the Ambulatory cohort (Cohort A) and will begin in the Hospitalized cohort (Cohort B). Hospitalized patients (Cohort B) with moderate but not severe COVID-19 will be enrolled and randomized to Peginterferon lambda 180µg on Day 1 and 8, or best supportive care. The primary endpoint will be the proportion positive for SARS-CoV-2 by nasopharyngeal swab on Day 15. In addition to the primary endpoints on which the study is powered, numerous secondary endpoints will be evaluated. Samples will also be collected for ancillary studies to better understand predictors of disease severity and response to treatment.

Study team
Jordan Feld
Dr. Jordan Feld
MD
University Health Network, Toronto
Trial name Post-exposure Prophylaxis (PEP) or Preemptive Therapy for COVID-19: A Pragmatic Randomized Clinical Trial
Type of trial Phase III
Trial ID NCT 04308668
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec, Manitoba, Alberta, Ontario
Trial description

This study is to test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus, as well as if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.

Study team
Todd C. Lee
Todd C. Lee, MD, MPH, FIDSA
Associate Professor in the Department of Medicine
McGill University
Ryan Zarychanski
Ryan Zarychanski
MD
University of Manitoba
Lauren E. Kelly
Lauren E. Kelly, PhD, MSc, CCRP
Clinical Trialist and Certified Clinical Research Professional with SoCRA
Organization
IIan Schwartz
IIan Schwartz
MD
University of Alberta
Emily McDonald
Emily McDonald, MD, MSc, FRCPC
Assistant Professor of Medicine
Organization
Dr. Zain Chagla
Dr. Zain Chagla
MD MSc FRCPC DTMH
McMaster University
Trial name Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-Exposure Prophylaxis: A randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada
Type of trial Pending
Trial ID N/A
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario
Trial description

This study aims to evaluate whether hydroxychloroquine (HCQ), a well-tolerated drug typically used in the prevention of malaria transmission and rheumatic disease, taken before and during exposure to patients with COVID-19 is effective in reducing COVID-19 infections among ED HCW.

Study team
Megan Landes
Megan Landes
Clinical Investigator
Toronto General Hospital Research Institute (TGHRI)
Trial name Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)M)
Type of trial Phase IV
Trial ID NCT 02735707
Health Canada Status Health Canada pending
Trial Status Open
Location
Ontario, Alberta, Manitoba, Quebec
Trial description

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome ofon patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness.

Study team
John Marshall
John Marshall
MD
Director, Critical Care Research, St. Michael’s Hospital, Unity Health
Srinivas Murthy
Srinivas Murthy
MD
BC Children’s Hospital Research Institute
Trial name Sarilumab COVID-19
Type of trial Phase II | Phase III
Trial ID NCT04327388
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec, Ontario, British Columbia
Trial description

Phase 2: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19 Phase 3: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19

Study team
Trial name Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia
Type of trial Pending
Trial ID NCT 04331665
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
Ontario
Trial description

The purpose of this study is to determine the safety and efficacy of the drug ruxolitinib in people diagnosed with COVID-19 pneumonia by determining the number of people whose conditions worsen (requiring machines to help with breathing or needing supplemental oxygen) while receiving the drug.

Study team
Steven Chan
Steven Chan
MD, PhD
Princess Margaret Cancer Centre
Vikas Gupta
Vikas Gupta
MD
Princess Margaret Cancer Centre
Trial name Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)
Type of trial Phase II
Trial ID NCT 04330690
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
Alberta, British Columbia, Ontario, Quebec, Manitoba, Saskatchewan, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Yukon, Northwest Territories, Nunavut
Trial description

This study is an adaptive, randomized, open-label, controlled clinical trial.Subjects will be randomized to receive either standard-of-care products or the study medication plus standard of care, while being hospitalized for COVID-19. Lopinavir/ritonavir will be administered 400 mg/100 mg orally (or weight based dose adjustment for children) for a 14-day course, or until discharge from hospital, whichever occurs first

Study team
Nelson Lee
Nelson Lee
MD
University of Alberta Hospital
Allison Mah
Allison Mah
MD
Vancouver General Hospital,
Natasha Press
Natasha Press
MD
St Paul’s Hospital
Shane English
Shane English
MD
The Ottawa Hospital
Robert Fowler
Robert Fowler
MD
Sunnybrook Health Sciences Centre
Bryan Coburn
Bryan Coburn
MD
Toronto Western Hospital
Matthew Cheng
Matthew Cheng
MD
McGill University Health Centre-Glen Site Royal Victoria HospitalRecruiting
Alexis Turgeon
Alexis Turgeon
MD
CHU de Québec – Université LavalRecruiting
Francois Lellouche
Francois Lellouche
MD
Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université LavalRecruiting
Francois Lamontagne
Francois Lamontagne
MD, FRCPC, MSc
Université de Sherbrooke and CIUSSS de l’Estrie – CHUS